Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.

Wang L, Jia D, Duan F, Sun Z, Liu X, Zhou L, Sun L, Ren S, Ruan Y, Gu J.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):687-92. doi: 10.1016/j.bbrc.2012.05.056. Epub 2012 May 23.

PMID:
22634008
2.

Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.

Manov I, Pollak Y, Broneshter R, Iancu TC.

FEBS J. 2011 Sep;278(18):3494-507. doi: 10.1111/j.1742-4658.2011.08271.x.

3.

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.

Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836.

PMID:
20799354
4.

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.

Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL.

J Hepatol. 2010 Jan;52(1):88-95. doi: 10.1016/j.jhep.2009.10.011. Epub 2009 Oct 23.

PMID:
19913321
5.

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.

J Hepatol. 2010 Jan;52(1):79-87. doi: 10.1016/j.jhep.2009.10.008. Epub 2009 Oct 28.

PMID:
19910069
6.
7.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

8.

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.

Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.

J Hepatol. 2011 Nov;55(5):1041-8. doi: 10.1016/j.jhep.2011.01.047. Epub 2011 Feb 24.

PMID:
21354226
9.

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.

World J Gastroenterol. 2011 Sep 14;17(34):3922-32. doi: 10.3748/wjg.v17.i34.3922.

10.

Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.

Tochizawa S, Masumori N, Yanai Y, Ohmoto Y, Yabuuchi Y, Tsukamoto T.

Biomed Res. 2008 Dec;29(6):271-8.

11.

Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.

Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY, Dai Z, Peng YF, Gu CY, Qiu SJ, Fan J.

Autophagy. 2011 Oct;7(10):1159-72. doi: 10.4161/auto.7.10.16818. Epub 2011 Oct 1.

PMID:
21691147
12.

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.

Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.

Mol Cancer Ther. 2012 Feb;11(2):452-63. doi: 10.1158/1535-7163.MCT-11-0412. Epub 2011 Dec 16.

13.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
14.

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.

Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.

Anticancer Res. 2012 Jul;32(7):2531-6.

PMID:
22753710
15.

Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.

Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.

Biochem Pharmacol. 2012 Mar 15;83(6):769-77. doi: 10.1016/j.bcp.2011.12.035. Epub 2012 Jan 2.

PMID:
22230479
16.

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.

Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.

Clin Cancer Res. 2008 Aug 15;14(16):5124-30. doi: 10.1158/1078-0432.CCR-07-4774.

17.

Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.

Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B, Lee SK.

Cancer Lett. 2010 Jan 28;287(2):196-206. doi: 10.1016/j.canlet.2009.06.011. Epub 2009 Jul 17.

PMID:
19616371
18.

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.

Wei G, Wang M, Hyslop T, Wang Z, Carr BI.

Int J Cancer. 2010 Dec 15;127(12):2949-58. doi: 10.1002/ijc.25498.

20.

c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.

Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG.

Cancer Biol Ther. 2011 Sep 15;12(6):531-8. doi: 10.4161/cbt.12.6.16053. Epub 2011 Sep 15.

PMID:
21734462

Supplemental Content

Support Center